Treatments with ICIs, including antibodies against cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programmed cell death-1 (PD-1), activate the immune system and have shown anti-tumor effects with increasing survival rates in advanced melanoma patients [2]. This evidence concerns the gene PDCD1 and melanoma.